FDA Ivonescimab Letter Raises Concerns Over China-Heavy Lung Cancer Trial Data
The FDA's published rejection letter says 93% of progression-free survival events in Summit Therapeutics' ivonescimab trial came from China, leaving its benefit for U.S. patients uncertain.
Medical Daily ·